Contact
searchSearch
HMP Global

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

September 2011 - FRMC

Cited Studies on Biomarker Discoveries Prone to Exaggerating Effects
09/19/2011
Studies are increasingly linking biomarkers to disease risk, treatment response, and disease progression. A recent literature review in the Journal of the American Medical Association [2011;305(21):2200-2207] indicates that some associations...
Studies are increasingly linking biomarkers to disease risk, treatment response, and disease progression. A recent literature review in the Journal of the American Medical Association [2011;305(21):2200-2207] indicates that some associations...
Studies are increasingly linking...
09/19/2011
First Report Managed Care
Telaprevir Improves Outcomes in Some Patients with Hepatitis C
09/19/2011
Chicago—An analytic model used to calculate long-term outcomes for hypothetical patients with the hepatitis C virus (HCV) projected that patients treated with a combination of telaprevir and peginterferon/ribavirin (PR) would survive between...
Chicago—An analytic model used to calculate long-term outcomes for hypothetical patients with the hepatitis C virus (HCV) projected that patients treated with a combination of telaprevir and peginterferon/ribavirin (PR) would survive between...
Chicago—An analytic model used...
09/19/2011
First Report Managed Care
Linaclotide Significantly Improves Quality of Life and Abdominal Symptoms
09/19/2011
Trials comparing linaclotide with placebo found that a daily dose reduced the severity of chronic constipation and improveed quality of life. 
Trials comparing linaclotide with placebo found that a daily dose reduced the severity of chronic constipation and improveed quality of life. 
Trials comparing linaclotide...
09/19/2011
First Report Managed Care
Comparing Adjuvant Chemotherapy Regimens in Non–Small-Cell Lung Cancer
09/19/2011
Chicago—A randomized phase 2 trial found that cisplatin plus pemetrexed was a safe and effective adjuvant chemotherapy regimen for patients with early-stage non–small-cell lung cancer (NSCLC). Patients taking cisplatin plus pemetrexed...
Chicago—A randomized phase 2 trial found that cisplatin plus pemetrexed was a safe and effective adjuvant chemotherapy regimen for patients with early-stage non–small-cell lung cancer (NSCLC). Patients taking cisplatin plus pemetrexed...
Chicago—A randomized phase 2...
09/19/2011
First Report Managed Care
Six-Year Follow-Up of Lenalidomide for Multiple Myeloma
09/19/2011
Chicago—After 6 years of follow-up in a phase 2 trial, researchers found that a combination therapy of dexamethasone, lenalidomide, and clarithromycin remained an effective regimen for patients who were newly diagnosed with multiple myeloma....
Chicago—After 6 years of follow-up in a phase 2 trial, researchers found that a combination therapy of dexamethasone, lenalidomide, and clarithromycin remained an effective regimen for patients who were newly diagnosed with multiple myeloma....
Chicago—After 6 years of...
09/19/2011
First Report Managed Care
Glucose-Lowering Effect of Insulin Degludec
09/19/2011
San Diego—In a randomized, double-blind, 2-period, crossover trial, researchers found the glucose-lowering effect of insulin degludec was evenly distributed in the first and second 12-hour periods in patients with type 2 diabetes. They also...
San Diego—In a randomized, double-blind, 2-period, crossover trial, researchers found the glucose-lowering effect of insulin degludec was evenly distributed in the first and second 12-hour periods in patients with type 2 diabetes. They also...
San Diego—In a randomized,...
09/19/2011
First Report Managed Care
Cost of Comorbidities in Obese Adults
09/19/2011
San Diego—Using data from research databases, researchers confirmed that patients with a body mass index (BMI) ≥35 kg/m2 had a higher prevalence of and costs associated with comorbidities compared with patients who had a BMI between 25 and...
San Diego—Using data from research databases, researchers confirmed that patients with a body mass index (BMI) ≥35 kg/m2 had a higher prevalence of and costs associated with comorbidities compared with patients who had a BMI between 25 and...
San Diego—Using data from...
09/19/2011
First Report Managed Care
Pooled Analysis of Exenatide to Treat Type 2 Diabetes
09/19/2011
San Diego—A pooled analysis of 16 studies found that patients with type 2 diabetes treated with exenatide twice daily or once weekly had significant improvements in hemoglobin A1c (HbA1c) level, fasting glucose, body weight, and systolic...
San Diego—A pooled analysis of 16 studies found that patients with type 2 diabetes treated with exenatide twice daily or once weekly had significant improvements in hemoglobin A1c (HbA1c) level, fasting glucose, body weight, and systolic...
San Diego—A pooled analysis of...
09/19/2011
First Report Managed Care
Oral Antidiabetics for Type 2 Diabetes and Chronic Kidney Disease
09/19/2011
San Diego—An examination of electronic health record data from an integrated health system found that patients with type 2 diabetes and chronic kidney disease who had an oral antidiabetic drug regimen concordant with National Kidney...
San Diego—An examination of electronic health record data from an integrated health system found that patients with type 2 diabetes and chronic kidney disease who had an oral antidiabetic drug regimen concordant with National Kidney...
San Diego—An examination of...
09/19/2011
First Report Managed Care
Saxagliptin Safe, Effective after 4 Years
09/19/2011
San Diego—After examining 4-year extensions of 2 randomized, double-blind, placebo-controlled trials, researchers found that patients with type 2 diabetes who took saxagliptin alone or in combination with metformin tolerated the medication....
San Diego—After examining 4-year extensions of 2 randomized, double-blind, placebo-controlled trials, researchers found that patients with type 2 diabetes who took saxagliptin alone or in combination with metformin tolerated the medication....
San Diego—After examining 4-year...
09/19/2011
First Report Managed Care

Advertisement

Advertisement

Advertisement

FRMC Volume 21, Issue 3

Current Issue

September 2024
Volume 21
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

What's Trending?

News
Novartis Says Experimental Drug Helps Chronic Migraine Sufferers
09/19/2016
About 40 percent of chronic migraine sufferers taking an experimental drug developed by Novartis and Amgen saw the number of days they suffered a migraine cut by at least half, beating the placebo in the trial.
About 40 percent of chronic migraine sufferers taking an experimental drug developed by Novartis and Amgen saw the number of days they suffered a migraine cut by at least half, beating the placebo in the trial.
About 40 percent of chronic...
09/19/2016
First Report Managed Care
Headshot of Lawrence Green, MD
Interview
Treatment Considerations for Pediatric vs Adult Patients With Atopic Dermatitis
07/29/2022
Lawrence J Green, MD, clinical professor of dermatology, George Washington University School of Medicine, reviews how clinicians approach treatment options for atopic dermatitis, as well as where the future of care my be headed as more agents...
Lawrence J Green, MD, clinical professor of dermatology, George Washington University School of Medicine, reviews how clinicians approach treatment options for atopic dermatitis, as well as where the future of care my be headed as more agents...
Lawrence J Green, MD, clinical...
07/29/2022
First Report Managed Care
Challenges for Medicaid as Membership Volume Swells
05/24/2012
San Francisco—The passing of the Patient Protection and Affordable Care Act (ACA) is presenting increasing challenges for managed Medicaid programs, which have already experienced steady growth decade by decade, according to information...
San Francisco—The passing of the Patient Protection and Affordable Care Act (ACA) is presenting increasing challenges for managed Medicaid programs, which have already experienced steady growth decade by decade, according to information...
San Francisco—The passing of the...
05/24/2012
First Report Managed Care
News
FDA wants further testing of Lilly pancreas drug
04/25/2011
04/25/2011
First Report Managed Care
News
FDA Unveils Tamper-Resistant Opioid Plan
01/10/2013
01/10/2013
First Report Managed Care

Video Insights

Videos
Bridging the Gaps in Prior Authorization: Challenges, Solutions, and Collaboration for Better Patient Care
11/13/2024
David Sand, MD, MBA, chief medical officer at ZeOmega, discusses the challenges of prior authorization, emphasizing the need for transparency, evidence-based standards, collaboration between payers and providers, and the potential for...
David Sand, MD, MBA, chief medical officer at ZeOmega, discusses the challenges of prior authorization, emphasizing the need for transparency, evidence-based standards, collaboration between payers and providers, and the potential for...
David Sand, MD, MBA, chief...
11/13/2024
First Report Managed Care
Richard Lipton, MD
Videos
The Evolving Role of CGRP-targeting Therapies in Migraine Prevention
10/31/2024
Richard Lipton, MD, provides insights on the American Headache Society’s position statement update on calcitonin gene-related peptide (CGRP)-targeting therapies as a first-line option for the prevention of migraine.
Richard Lipton, MD, provides insights on the American Headache Society’s position statement update on calcitonin gene-related peptide (CGRP)-targeting therapies as a first-line option for the prevention of migraine.
Richard Lipton, MD, provides...
10/31/2024
First Report Managed Care
Alexander Spira, MD, PhD
Videos
Unmet Needs in the Treatment and Management of Non–Small Cell Lung Cancer
09/26/2024
Alexander I. Spira, MD, PhD, discusses significant unmet needs in the treatment and management of non–small cell lung cancer (NSCLC).
Alexander I. Spira, MD, PhD, discusses significant unmet needs in the treatment and management of non–small cell lung cancer (NSCLC).
Alexander I. Spira, MD, PhD,...
09/26/2024
First Report Managed Care
Videos
Treatment Options for NSCLC: A Discussion on Coverage, Clinical Outcomes, and Payer Perspectives
09/25/2024
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Learn about research...
09/25/2024
First Report Managed Care
Title Card
Videos
Addressing the Root Cause of a Common Ocular Condition: A Virtual Roundtable
09/04/2024
View a roundtable discussion on Demodex blepharitis, a prevalent ocular condition that often goes undiagnosed in patients.
View a roundtable discussion on Demodex blepharitis, a prevalent ocular condition that often goes undiagnosed in patients.
View a roundtable discussion on...
09/04/2024
First Report Managed Care
Jordan Bazinsky
Videos
Addressing Health Disparities and Promoting Equity: The Role of Advanced Imaging Solutions
08/15/2024
Guest expert Jordan Bazinsky discusses the challenges facing the medical imaging industry, the potential of AI and emerging technologies, the role of advanced imaging solutions in promoting health equity, and the key trends and challenges...
Guest expert Jordan Bazinsky discusses the challenges facing the medical imaging industry, the potential of AI and emerging technologies, the role of advanced imaging solutions in promoting health equity, and the key trends and challenges...
Guest expert Jordan Bazinsky...
08/15/2024
First Report Managed Care
Farrukh Awan, MD
Videos
Promising Therapies and Clinical Trials for Chronic Lymphocytic Leukemia
08/14/2024
Farrukh Awan, MD, highlights promising therapies and clinical trials within the field of chronic lymphocytic leukemia (CLL).
Farrukh Awan, MD, highlights promising therapies and clinical trials within the field of chronic lymphocytic leukemia (CLL).
Farrukh Awan, MD, highlights...
08/14/2024
Journal of Clinical Pathways
Hayward
Videos
Evolving Health Care Contact Centers Into Drivers of Value-Based Care
07/31/2024
Discover how health care contact centers can transform into drivers of value-based care through AI, automation, upskilling agents, and rethinking workflows and metrics to improve patient outcomes and population health.
Discover how health care contact centers can transform into drivers of value-based care through AI, automation, upskilling agents, and rethinking workflows and metrics to improve patient outcomes and population health.
Discover how health care contact...
07/31/2024
First Report Managed Care
Lucille Accetta Headshot
Videos
Enhancing Patient Medication Adherence: Insights and Strategies From Asembia 2024
06/11/2024
Lucille Accetta, PharmD, MBA, MSPH, Senior Vice President of CVS Specialty Operations
Key stakeholders in the health care industry gathered to discuss prevalent topics at this year's Asembia annual summit. Medication adherence emerged as one of the most talked-about issues. In a session led by Lucille Accetta, PharmD, MBA,...
Key stakeholders in the health care industry gathered to discuss prevalent topics at this year's Asembia annual summit. Medication adherence emerged as one of the most talked-about issues. In a session led by Lucille Accetta, PharmD, MBA,...
Key stakeholders in the health...
06/11/2024
First Report Managed Care
Melissa Andel, Principal, CommonHealth Solutions, LLC
Videos
Navigating the Impact of the Inflation Reduction Act: Implications for Payers, Patients, and Manufacturers
05/24/2024
Melissa Andel, Principal, CommonHealth Solutions, LLC
Learn about the impacts of the Inflation Reduction Act on payers and patients, highlighting the changes in Medicare benefits and drug coverage coming in 2025 and 2026.
Learn about the impacts of the Inflation Reduction Act on payers and patients, highlighting the changes in Medicare benefits and drug coverage coming in 2025 and 2026.
Learn about the impacts of the...
05/24/2024
First Report Managed Care

Subscribe to our eNewsletters!

First Report Managed Care Newsletter

September 2011 Volume 8 Issue 9

View Issue Archive
Editorial Correspondence

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement